Precision medicine in inflammatory bowel disease: concept, progress and challenges
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Crohn’s disease and ulcerative colitis are increasingly prevalent, relapsing and remitting inflammatory bowel diseases (IBDs) with variable disease courses and complications. Their aetiology remains unclear but current evidence shows an increasingly complex pathophysiology broadly centring on the genome, exposome, microbiome and immunome. Our increased understanding of disease pathogenesis is providing an ever-expanding arsenal of therapeutic options, but these can be expensive and patients can lose response or never respond to certain therapies. Therefore, there is now a growing need to personalise therapies on the basis of the underlying disease biology and a desire to shift our approach from “reactive” management driven by disease complications to “proactive” care with an aim to prevent disease sequelae. Precision medicine is the tailoring of medical treatment to the individual patient, encompassing a multitude of data-driven (and multi-omic) approaches to foster accurate clinical decision-making. In IBD, precision medicine would have significant benefits, enabling timely therapy that is both effective and appropriate for the individual. In this review, we summarise some of the key areas of progress towards precision medicine, including predicting disease susceptibility and its course, personalising therapies in IBD and monitoring response to therapy. We also highlight some of the challenges to be overcome in order to deliver this approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32448-0 · Cited by 6,087
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722
Self-citationUnravelling the pathogenesis of inflammatory bowel disease
Xavier, R. J., & Podolsky, D. K. (2007) · Nature · doi:10.1038/nature06005 · Cited by 4,364
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S. J., Yassour, M., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.005 · Cited by 3,220
Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases
Lloyd-Price, J., Arze, C., Ananthakrishnan, A. N., Schirmer, M., Avila-Pacheco, J., Poon, T. W., Andrews, E., Ajami, N. J., Bonham, K. S., Brislawn, C. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1237-9 · Cited by 3,143
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039
The global burden of IBD: from 2015 to 2025
Kaplan, G. G. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.150 · Cited by 2,639
Liu, J. Z., van Sommeren, S., Huang, H., Ng, S. C., Alberts, R., Takahashi, A., Ripke, S., Lee, J. C., Jostins, L., Shah, T., et al. (2015) · Nature Genetics · doi:10.1038/ng.3359 · Cited by 2,603
Peery, A. F., Crockett, S. D., Murphy, C. C., Lund, J. L., Dellon, E. S., Williams, J. L., Jensen, E. T., Shaheen, N. J., Barritt, A. S., Lieber, S. R., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.08.063 · Cited by 1,619
Immunopathogenesis of IBD: current state of the art
de Souza, H. S. P., & Fiocchi, C. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.186 · Cited by 1,551
de Lange, K. M., Moutsianas, L., Lee, J. C., Lamb, C. A., Luo, Y., Kennedy, N. A., Jostins, L., Rice, D. L., Gutierrez-Achury, J., Ji, S.-G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3760 · Cited by 1,445
Self-citationEnvironmental triggers in IBD: a review of progress and evidence
Ananthakrishnan, A. N., Bernstein, C. N., Iliopoulos, D., Macpherson, A., Neurath, M. F., Ali, R. A. R., Vavricka, S. R., & Fiocchi, C. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.136 · Cited by 948
Shen, R., Olshen, A. B., & Ladanyi, M. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp543 · Cited by 849
Lewis, J. D., Chen, E. Z., Baldassano, R. N., Otley, A. R., Griffiths, A. M., Lee, D., Bittinger, K., Bailey, A., Friedman, E. S., Hoffmann, C., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.09.008 · Cited by 823
Detecting shared pathogenesis from the shared genetics of immune-related diseases
Zhernakova, A., van Diemen, C. C., & Wijmenga, C. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2489 · Cited by 551
Ananthakrishnan, A. N., Luo, C., Yajnik, V., Khalili, H., Garber, J. J., Stevens, B. W., Cleland, T., & Xavier, R. J. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.04.010 · Cited by 451
Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data
Coward, S., Clement, F., Benchimol, E. I., Bernstein, C. N., Avina-Zubieta, J. A., Bitton, A., Carroll, M. W., Hazlewood, G., Jacobson, K., Jelinski, S., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.002 · Cited by 449
The IBD interactome: an integrated view of aetiology, pathogenesis and therapy
de Souza, H. S. P., Fiocchi, C., & Iliopoulos, D. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.110 · Cited by 447
Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
Abreu, M. T., Taylor, K. D., Lin, Y.-C., Hang, T., Gaiennie, J., Landers, C. J., Vasiliauskas, E. A., Kam, L. Y., Rojany, M., Papadakis, K. A., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.35393 · Cited by 428
Lee, J. C., Lyons, P. A., McKinney, E. F., Sowerby, J. M., Carr, E. J., Bredin, F., Rickman, H. M., Ratlamwala, H., Hatton, A., Rayner, T. F., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci59255 · Cited by 304
Lee, J. C., Biasci, D., Roberts, R., Gearry, R. B., Mansfield, J. C., Ahmad, T., Prescott, N. J., Satsangi, J., Wilson, D. C., Jostins, L., et al. (2017) · Nature Genetics · doi:10.1038/ng.3755 · Cited by 304
Self-citationTranscriptional risk scores link GWAS to eQTLs and predict complications in Crohn's disease
Marigorta, U. M., Denson, L. A., Hyams, J. S., Mondal, K., Prince, J., Walters, T. D., Griffiths, A., Noe, J. D., Crandall, W. V., Rosh, J. R., et al. (2017) · Nature Genetics · doi:10.1038/ng.3936 · Cited by 166
Big data in IBD: a look into the future
Olivera, P., Danese, S., Jay, N., Natoli, G., & Peyrin-Biroulet, L. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0102-5 · Cited by 151
The future of precision medicine: potential impacts for health technology assessment
Love-Koh, J., Peel, A., Rejon-Parrilla, J. C., Ennis, K., Lovett, R., Manca, A., Chalkidou, A., Wood, H., & Taylor, M. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0686-6 · Cited by 131
Research works printed but not linked: 121
- J Torres, 2017, Crohn's disease., Lancet., 389, 1741-55, 10.1016/S0140-6736(16)31711-1 · DOI · Paper page
- R Ungaro, 2017, Ulcerative colitis., Lancet., 389, 1756-70, 10.1016/S0140-6736(16)32126-2 · DOI · Paper page
- N Molodecky, 2012, Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review., Gastroenterology., 142, 46-54.e42; quiz e30, 10.1053/j.gastro.2011.10.001 · DOI · Paper page
- J Sýkora, 2018, Current global trends in the incidence of pediatric-onset inflammatory bowel disease., World J Gastroenterol., 24, 2741-63, 10.3748/wjg.v24.i25.2741 · DOI · Paper page
- B Verstockt, 2018, Genome-wide association studies in Crohn's disease: Past, present and future., Clin Transl Immunology., 7, e1001, 10.1002/cti2.1001 · DOI
- J McIlroy, 2018, Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management., Aliment Pharmacol Ther., 47, 26-42, 10.1111/apt.14384 · DOI · Paper page
- S Paramsothy, 2018, The current state of the art for biological therapies and new small molecules in inflammatory bowel disease., Mucosal Immunol., 11, 1558-70, 10.1038/s41385-018-0050-3 · DOI
- R Weisshof, 2018, Emerging Therapies for Inflammatory Bowel Disease., Adv Ther., 35, 1746-62, 10.1007/s12325-018-0795-9 · DOI · Paper page
- B Verstockt, 2018, New treatment options for inflammatory bowel diseases., J Gastroenterol., 53, 585-90, 10.1007/s00535-018-1449-z · DOI · Paper page
- S Odes, 2008, How expensive is inflammatory bowel disease? A critical analysis., World J Gastroenterol., 14, 6641-7, 10.3748/wjg.14.6641 · doi:10.3748/wjg.14.6641
- J Reinglas, 2018, Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases., World J Gastroenterol., 24, 3567-82, 10.3748/wjg.v24.i32.3567 · DOI
- J Burisch, 2013, The burden of inflammatory bowel disease in Europe., J Crohns Colitis., 7, 322-37, 10.1016/j.crohns.2013.01.010 · DOI · Paper page
- C Bähler, 2017, Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014., BMC Gastroenterol., 17, 138, 10.1186/s12876-017-0681-y · DOI · Paper page
- S Singh, 2018, Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis., J Crohns Colitis., 12, 635-43, 10.1093/ecco-jcc/jjy004 · DOI · Paper page
- J Lee, 2012, Predicting the course of IBD: light at the end of the tunnel?, Dig Dis., 30 Suppl 1, 95-9, 10.1159/000341132 · DOI
- J Lewis, 2011, The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease., Gastroenterology., 140, 1817-1826.e2, 10.1053/j.gastro.2010.11.058 · DOI · Paper page
- E Viennois, 2015, Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine., Inflamm Bowel Dis., 21, 2467-74, 10.1097/MIB.0000000000000444 · DOI
- T Stevens, 2018, Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy., Aliment Pharmacol Ther., 48, 1213-31, 10.1111/apt.15033 · DOI
- M Orholm, 1999, Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease., Am J Gastroenterol., 94, 3236-8, 10.1111/j.1572-0241.1999.01526.x · DOI
- M Spehlmann, 2008, Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study., Inflamm Bowel Dis., 14, 968-76, 10.1002/ibd.20380 · DOI · Paper page
- F Moller, 2015, Familial risk of inflammatory bowel disease: a population-based cohort study 1977-2011., Am J Gastroenterol., 110, 564-71, 10.1038/ajg.2015.50 · DOI · Paper page
- D McGovern, 2015, Genetics of Inflammatory Bowel Diseases., Gastroenterology., 149, 1163-1176.e2, 10.1053/j.gastro.2015.08.001 · DOI · Paper page
- G Ramos, 2019, Mechanisms of Disease: Inflammatory Bowel Diseases., Mayo Clin Proc., 94, 155-65, 10.1016/j.mayocp.2018.09.013 · DOI · Paper page
- M Zhao, 2019, Impact of Genes and the Environment on the Pathogenesis and Disease Course of Inflammatory Bowel Disease., Dig Dis Sci., 64, 1759-69, 10.1007/s10620-019-05648-w · DOI
- L Rigottier-Gois, 2013, Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis., ISME J., 7, 1256-61, 10.1038/ismej.2013.80 · DOI · Paper page
- J Park, 2017, IBD immunopathogenesis: A comprehensive review of inflammatory molecules., Autoimmun Rev., 16, 416-26, 10.1016/j.autrev.2017.02.013 · DOI · Paper page
- M Rescigno, 2009, Dendritic cells in intestinal homeostasis and disease., J Clin Invest., 119, 2441-50, 10.1172/JCI39134 · DOI · Paper page
- B Ahluwalia, 2018, Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies., Scand J Gastroenterol., 53, 379-89, 10.1080/00365521.2018.1447597 · DOI · Paper page
- G Ginsburg, 2018, Precision Medicine: From Science To Value., Health Aff (Millwood)., 37, 694-701, 10.1377/hlthaff.2017.1624 · DOI · Paper page
- I Solberg, 2009, Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)., Scand J Gastroenterol., 44, 431-40, 10.1080/00365520802600961 · DOI · Paper page
- I Solberg, 2007, Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study., Clin Gastroenterol Hepatol., 5, 1430-8, 10.1016/j.cgh.2007.09.002 · DOI · Paper page
- L Beaugerie, 2012, Clinical, serological and genetic predictors of inflammatory bowel disease course., World J Gastroenterol., 18, 3806-13, 10.3748/wjg.v18.i29.3806 · DOI
- L Peyrin-Biroulet, 2016, Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions., Clin Gastroenterol Hepatol., 14, 348-354.e17, 10.1016/j.cgh.2015.06.001 · DOI · Paper page
- M Hong, 2018, Immunochip Meta-Analysis of Inflammatory Bowel Disease Identifies Three Novel Loci and Four Novel Associations in Previously Reported Loci., J Crohns Colitis., 12, 730-41, 10.1093/ecco-jcc/jjy002 · DOI
- S Girardin, 2003, Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing., Trends Immunol., 24, 652-8, 10.1016/j.it.2003.10.007 · DOI
- S Lesage, 2002, CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease., Am J Hum Genet., 70, 845-57, 10.1086/339432 · DOI · Paper page
- A Cuthbert, 2002, The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease., Gastroenterology., 122, 867-74, 10.1053/gast.2002.32415 · DOI · Paper page
- I Cleynen, 2013, Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project., Gut., 62, 1556-65, 10.1136/gutjnl-2011-300777 · DOI · Paper page
- M Salem, 2015, ATG16L1: A multifunctional susceptibility factor in Crohn disease., Autophagy., 11, 585-94, 10.1080/15548627.2015.1017187 · DOI · Paper page
- E Fowler, 2008, ATG16L1 T300A shows strong associations with disease subgroups in a large Australian IBD population: further support for significant disease heterogeneity., Am J Gastroenterol., 103, 2519-26, 10.1111/j.1572-0241.2008.02023.x · DOI
- A Latiano, 2009, Polymorphism of the IRGM gene might predispose to fistulizing behavior in Crohn's disease., Am J Gastroenterol., 104, 110-6, 10.1038/ajg.2008.3 · DOI
- P Deepak, 2017, Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease., Gastroenterol Clin North Am., 46, 603-26, 10.1016/j.gtc.2017.05.013 · DOI
- T Okazaki, 2008, Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a population-based case-control study: evidence of gene-gene interactions., Inflamm Bowel Dis., 14, 1528-41, 10.1002/ibd.20512 · DOI
- I Cleynen, 2016, Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study., Lancet., 387, 156-67, 10.1016/S0140-6736(15)00465-1 · DOI · Paper page
- V Pascal, 2017, A microbial signature for Crohn's disease., Gut., 66, 813-22, 10.1136/gutjnl-2016-313235 · DOI · Paper page
- E Papa, 2012, Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease., PLoS One., 7, e39242, 10.1371/journal.pone.0039242 · DOI · Paper page
- H Somineni, 2019, The Microbiome in Patients With Inflammatory Diseases., Clin Gastroenterol Hepatol., 17, 243-55, 10.1016/j.cgh.2018.08.078 · DOI
- P van Rheenen, 2010, Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis., BMJ., 341, c3369, 10.1136/bmj.c3369 · DOI · Paper page
- N Kennedy, 2015, Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16–50 years., J Crohns Colitis., 9, 41-9, 10.1016/j.crohns.2014.07.005 · DOI
- C Maréchal, 2017, Compliance with the faecal calprotectin test in patients with inflammatory bowel disease., United European Gastroenterol J., 5, 702-7, 10.1177/2050640616686517 · DOI
- R Kalla, 2018, Patients’ perceptions of faecal calprotectin testing in inflammatory bowel disease: Results from a prospective multicentre patient-based survey., Scand J Gastroenterol., 53, 1437-42, 10.1080/00365521.2018.1527394 · DOI
- A Buisson, 2017, Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease., Inflamm Bowel Dis., 23, 1425-33, 10.1097/MIB.0000000000001140 · DOI · Paper page
- M Calafat, 2015, High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling?, Inflamm Bowel Dis., 21, 1072-6, 10.1097/MIB.0000000000000349 · DOI
- L Du, 2018, Within-Stool and Within-Day Sample Variability of Fecal Calprotectin in Patients With Inflammatory Bowel Disease: A Prospective Observational Study., J Clin Gastroenterol., 52, 235-40, 10.1097/MCG.0000000000000776 · DOI
- J Satsangi, 2016, How to Apply for and Secure EU Funding for Collaborative IBD Research Projects., J Crohns Colitis., 10, 363-70, 10.1093/ecco-jcc/jjv237 · doi:10.1093/ecco-jcc/jjv237
- S Vermeire, 2006, Laboratory markers in IBD: useful, magic, or unnecessary toys?, Gut., 55, 426-31, 10.1136/gut.2005.069476 · DOI · Paper page
- G Ho, 2009, Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis., Am J Gastroenterol., 104, 673-8
- N Kennedy, 2019, Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease., Clin Gastroenterol Hepatol., 17, 2269-2276.e4, 10.1016/j.cgh.2019.02.017 · DOI
- R Kalla, 2016, Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases., Am J Gastroenterol., 111, 1796-805, 10.1038/ajg.2016.342 · DOI · Paper page
- D Biasci, 2019, A blood-based prognostic biomarker in IBD., Gut., 68, 1386-95, 10.1136/gutjnl-2019-318343 · DOI · Paper page
- R Kalla, 2017, Proximity Extension Assay based Proteins Show Immune Cell Specificity and can Diagnose and Predict Outcomes in Inflammatory Bowel Diseases: IBD Character Study., Gastroenterology., 152, S606-S607, 10.1016/S0016-5085(17)32161-3 · doi:10.1016/s0016-5085(17)32161-3
- R Kalla, 2017, OC-047 Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease – ibd character., Gut., 66, A24-A5, 10.1136/gutjnl-2017-314472.47 · doi:10.1136/gutjnl-2017-314472.47
- N Ventham, 2016, Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease., Nat Commun., 7, 13507, 10.1038/ncomms13507 · DOI · Paper page
- I Trbojević Akmačić, 2015, Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome., Inflamm Bowel Dis., 21, 1237-47, 10.1097/MIB.0000000000000372 · DOI · Paper page
- A Shubhakar, 2019, DOP10 Serum N-glycomic biomarkers predict treatment escalation in inflammatory bowel disease., J Crohns Colitis., 13, S032-S033, 10.1093/ecco-jcc/jjy222.045 · doi:10.1093/ecco-jcc/jjy222.045
- L Beaugerie, 2006, Predictors of Crohn's disease., Gastroenterology., 130, 650-6, 10.1053/j.gastro.2005.12.019 · DOI · Paper page
- C Loly, 2009, Predictors of severe Crohn's disease., Scand J Gastroenterol., 43, 948-54, 10.1080/00365520801957149 · DOI · Paper page
- M Henriksen, 2007, Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study., Am J Gastroenterol., 102, 1955-63, 10.1111/j.1572-0241.2007.01368.x · DOI
- F Clerc, 2018, Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases., Gastroenterology., 155, 829-43, 10.1053/j.gastro.2018.05.030 · DOI
- F Wolters, 2005, Phenotype at diagnosis predicts recurrence rates in Crohn's disease., Gut., 55, 1124-30, 10.1136/gut.2005.084061 · DOI · Paper page
- O Höie, 2007, Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort., Am J Gastroenterol., 102, 1692-701, 10.1111/j.1572-0241.2007.01265.x · DOI · Paper page
- E Langholz, 1994, Course of ulcerative colitis: analysis of changes in disease activity over years., Gastroenterology., 107, 3-11, 10.1016/0016-5085(94)90054-x · DOI · Paper page
- O Hoie, 2007, Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years., Gastroenterology., 132, 507-5, 10.1053/j.gastro.2006.11.015 · DOI · Paper page
- S Kugathasan, 2017, Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study., Lancet., 389, 1710-8, 10.1016/S0140-6736(17)30317-3 · DOI · Paper page
- H Sokol, 2008, Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients., Proc Natl Acad Sci U S A., 105, 16731-6, 10.1073/pnas.0804812105 · DOI · Paper page
- Y Haberman, 2014, Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature., J Clin Invest., 124, 3617-33, 10.1172/JCI75436 · DOI · Paper page
- J Colombel, 2018, Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial., Lancet., 390, 2779-89, 10.1016/S0140-6736(17)32641-7 · DOI · Paper page
- S Yang, 2014, A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia., Nat Genet., 46, 1017-20, 10.1038/ng.3060 · DOI · Paper page
- T Moriyama, 2016, NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity., Nat Genet., 48, 367-73, 10.1038/ng.3508 · DOI · Paper page
- G Walker, 2019, Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease., JAMA., 321, 773-785, 10.1001/jama.2019.0709 · DOI · Paper page
- G Heap, 2014, HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants., Nat Genet., 46, 1131-4, 10.1038/ng.3093 · DOI · Paper page
- B Warner, 2018, A practical guide to thiopurine prescribing and monitoring in IBD., Frontline Gastroenterol., 9, 10-5, 10.1136/flgastro-2016-100738 · DOI
- N de Boer, 2018, Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives., J Crohns Colitis., 12, 610-20, 10.1093/ecco-jcc/jjx181 · DOI
- N Mitrev, 2017, Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases., Aliment Pharmacol Ther., 46, 1037-53, 10.1111/apt.14368 · DOI · Paper page
- C Steenholdt, 2014, Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial., Gut., 63, 919-27, 10.1136/gutjnl-2013-305279 · DOI · Paper page
- N Vande Casteele, 2015, Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease., Gastroenterology., 148, 1320-1329.e3, 10.1053/j.gastro.2015.02.031 · DOI · Paper page
- G D’Haens, 2018, Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease., Gastroenterology., 154, 1343-1351.e1, 10.1053/j.gastro.2018.01.004 · DOI · Paper page
- A Ricciuto, 2018, Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis., J Crohns Colitis., 12, 1302-15, 10.1093/ecco-jcc/jjy109 · DOI
- N West, 2017, Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease., Nat Med., 23, 579-89, 10.1038/nm.4307 · DOI · Paper page
- B Verstockt, 2019, Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease., EBioMedicine., 40, 733-42, 10.1016/j.ebiom.2019.01.027 · DOI · Paper page
- S Telesco, 2018, Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis., Gastroenterology., 155, 1008-1011.e8, 10.1053/j.gastro.2018.06.077 · DOI
- I Morilla, 2019, Colonic MicroRNA Profiles, Identified by a Deep Learning Algorithm, That Predict Responses to Therapy of Patients With Acute Severe Ulcerative Colitis., Clin Gastroenterol Hepatol., 17, 905-13, 10.1016/j.cgh.2018.08.068 · DOI · Paper page
- K Kolho, 2015, Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation., Am J Gastroenterol., 110, 921-30, 10.1038/ajg.2015.149 · DOI · Paper page
- M Doherty, 2018, Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients., mBio., 9, pii: e02120-17, 10.1128/mBio.02120-17 · DOI · Paper page
- N Kennedy, 2019, Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study., Lancet Gastroenterol Hepatol., 4, 341-53, 10.1016/S2468-1253(19)30012-3 · DOI · Paper page
- A Sazonovs, 2018, OP013 HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn’s disease., J Crohns Colitis., 12, S009-S010, 10.1093/ecco-jcc/jjx180.012 · DOI
- M Pereira, 2019, A [Glyco]biomarker that Predicts Failure to Standard Therapy in Ulcerative Colitis Patients., J Crohns Colitis., 13, 39-49, 10.1093/ecco-jcc/jjy139 · DOI
- Y Haberman, 2019, Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response., Nat Commun., 10, 38, 10.1038/s41467-018-07841-3 · DOI · Paper page
- K Cunningham, 2016, Peroxisome Proliferator-activated Receptor-γ Coactivator 1-α (PGC1α) Protects against Experimental Murine Colitis., J Biol Chem., 291, 10184-200, 10.1074/jbc.M115.688812 · DOI
- J Martin, 2019, Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy., Cell., 178, 1493-1508.e20, 10.1016/j.cell.2019.08.008 · DOI · Paper page
- C Ma, 2018, Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic Review., Clin Gastroenterol Hepatol., 16, 1407-1419.e22, 10.1016/j.cgh.2018.02.051 · DOI
- C Ma, 2018, Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set., Clin Gastroenterol Hepatol., 16, 637-647.e13, 10.1016/j.cgh.2017.08.025 · DOI
- L Peyrin-Biroulet, 2015, Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target., Am J Gastroenterol., 110, 1324-38, 10.1038/ajg.2015.233 · DOI · Paper page
- C Yzet, 2019, OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: Long-term data from CALM., J Crohns Colitis., 13, S024-S025, 10.1093/ecco-jcc/jjy222.032 · doi:10.1093/ecco-jcc/jjy222.032
- A Heida, 2017, Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide., Inflamm Bowel Dis., 23, 894-902, 10.1097/MIB.0000000000001082 · DOI · Paper page
- G DʼHaens, 2012, Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease., Inflamm Bowel Dis., 18, 2218-24, 10.1002/ibd.22917 · DOI · Paper page
- T Florin, 2006, Clinically active Crohn's disease in the presence of a low C-reactive protein., Scand J Gastroenterol., 41, 306-11, 10.1080/00365520500217118 · DOI
- R Boyapati, 2018, Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease., Cochrane Database Syst Rev., 5, CD012540, 10.1002/14651858.CD012540.pub2 · DOI
- E Louis, 2012, Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped., Gastroenterology., 142, 63-70.e5, 10.1053/j.gastro.2011.09.034 · DOI · Paper page
- N de Suray, 2012, 864 Close Monitoring of CRP and Fecal Calprotectin is Able to Predict Clinical Relapse in Patients With Crohn's Disease in Remission After Infliximab Withdrawal. a Sub-Analysis of the Stori Study., Gastroenterology., 142, S-149, 10.1016/S0016-5085(12)60560-5 · DOI
- N Planell, 2017, Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis., J Crohns Colitis., 11, 1335-46, 10.1093/ecco-jcc/jjx091 · DOI
- T Dierckx, 2019, GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD., J Crohns Colitis., 13, 389-94, 10.1093/ecco-jcc/jjy162 · DOI
- C Dai, 2018, Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis., J Gastroenterol Hepatol., 33, 990-7, 10.1111/jgh.14121 · DOI
- S Hiraoka, 2018, Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis., Gut Liver., 12, 142-8, 10.5009/gnl17013 · doi:10.5009/gnl17013
- K Shaw, 2016, Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease., Genome Med., 8, 75, 10.1186/s13073-016-0331-y · DOI · Paper page
- A Sitapati, 2017, Integrated precision medicine: the role of electronic health records in delivering personalized treatment., Wiley Interdiscip Rev Syst Biol Med., 9, 10.1002/wsbm.1378 · DOI · Paper page
- A Waljee, 2017, Machine Learning Algorithms for Objective Remission and Clinical Outcomes with Thiopurines., J Crohns Colitis., 11, 801-10, 10.1093/ecco-jcc/jjx014 · DOI · Paper page
- J Ashton, 2019, Personalising medicine in inflammatory bowel disease-current and future perspectives., Transl Pediatr., 8, 56-69, 10.21037/tp.2018.12.03 · DOI
- M Parkes, 2018, PRedicting Outcomes For Crohn's dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial., BMJ Open., 8, e026767, 10.1136/bmjopen-2018-026767 · DOI
- J Lee, 2017, OC-044 Profile trial: predicting outcomes for crohn’s disease using a molecular biomarker., Gut., 66, A22-A3, 10.1136/gutjnl-2017-314472.44 · DOI
- P Shannon, 2003, Cytoscape: a software environment for integrated models of biomolecular interaction networks., Genome Res., 13, 2498-504, 10.1101/gr.1239303 · DOI · Paper page
Cited by
Artificial intelligence in gastroenterology: A state-of-the-art review
Kröner, P. T., Engels, M. M., Glicksberg, B. S., Johnson, K. W., Mzaik, O., van Hooft, J. E., Wallace, M. B., El-Serag, H. B., & Krittanawong, C. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i40.6794 · Cited by 165
Erdmann, A., Rehmann-Sutter, C., & Bozzaro, C. (2021) · BMC Medical Ethics · doi:10.1186/s12910-021-00682-8 · Cited by 86
Artificial intelligence & clinical nutrition: What the future might have in store
Bond, A., Mccay, K., & Lal, S. (2023) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2023.07.082 · Cited by 79
Nowak, J. K., Adams, A. T., Kalla, R., Lindstrøm, J. C., Vatn, S., Bergemalm, D., Keita, Å. V., Gomollón, F., Jahnsen, J., Vatn, M. H., et al. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjac033 · Cited by 51
Self-citation
Metadata
- Authors
- Borg-Bartolo, S. P., Boyapati, R. K., Satsangi, J., & Kalla, R.
- Venue
- F1000Research
- Publisher
- F1000 Research Ltd
- Published
- 2020-01-28
- Volume
- 9
- Pages
- 54
- ISSN
- 2046-1402 (ISSN-L)
- OpenAlex
- W3003805058
- Cited by
- 90
- References
- 25
- FWCI
- 8.24
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.